Novo Nordisk ® ncluding the statutory An nual Report 2022 and Form 20-F, which both were filed with the SEC in ritten information released, or oral statements made, to the public in the future by or on behalf of plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘target’ and other l performance identify forward-looking statements. Examples of such forward-looking statements Novo Nordisk’s products, product research, product development, product introductions and er share, capital expenditures, dividends, capital structure, net financials and other financial es such as legal proceedings, and d-looking statements involve inherent risks and uncertainties, both general and specific. Novo ould cause actual results to differ materially from those contemplated in any forward-looking d economic conditions, such as interest rate and currency exchange rate fluctuations, delay or failure ies and production, including as a result of interruptions or delays affecting supply chains on which ntract breaches or terminations, government- mandated or market-driven price decreases for Novo g the risk of cybersecurit y b reeches, Novo Nordisk’s ability to successfully market current and new ental laws and related interpretation thereof, including on reimbursement, intellectual property actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic spute, failure to recruit and retain the right employees, failure to maintain a culture of compliance, rises, civil unrest, war or other conflict. the accuracy of forw ard-looking statements in this Annual Report 2022, reference is made to the ise any forward-looking statement after the distribution of this Annual Report 2022, whether as a
Download PDF file